Revisit  18 F-fluorodeoxyglucose oncology positron emission tomography: “systems molecular imaging” of glucose metabolism

Baozhong Shen; Tao Huang; Yingying Sun; Zhongnan Jin; Xiao-Feng Li

doi:10.18632/oncotarget.16647

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Revisit ¹⁸F-fluorodeoxyglucose oncology positron emission tomography: “systems molecular imaging” of glucose metabolism

Baozhong Shen _, Tao Huang, Yingying Sun, Zhongnan Jin and Xiao-Feng Li

PDF | HTML | How to cite

Oncotarget. 2017; 8:43536-43542. https://doi.org/10.18632/oncotarget.16647

Metrics: PDF 1758 views | HTML 2762 views | ?

Abstract

Baozhong Shen1,2, Tao Huang3,*, Yingying Sun1,2,*, Zhongnan Jin1,2 and Xiao-Feng Li1,2

1 PET/CT/MRI Center, The Fourth Hospital of Harbin Medical University, Harbin, China

2 Molecular Imaging Research Center, Harbin Medical University, Harbin, China

3 Department of Radiology, The Fourth Hospital of Harbin Medical University, Harbin, China

* These authors have contributed equally to this article

Correspondence to:

Baozhong Shen, email:

Xiao-Feng Li, email:

Keywords: ¹⁸F-FDG, positron emission tomography, cancer, hypoxia, glucose metabolism

Received: February 02, 2017 Accepted: March 11, 2017 Published: March 29, 2017

Abstract

18F-fluorodeoxyglucose (18F-FDG) positron emission tomography has become an important tool for detection, staging and management of many types of cancer. Oncology application of 18F-FDG bases on the knowledge that increase in glucose demand and utilization is a fundamental features of cancer. Pasteur effect, Warburg effect and reverse Warburg effect have been used to explain glucose metabolism in cancer. 18F-FDG accumulation in cancer is reportedly microenvironment-dependent, 18F-FDG avidly accumulates in poorly proliferating and hypoxic cancer cells, but low in well perfused (and proliferating) cancer cells. Cancer is a heterogeneous and complex “organ” containing multiple components, therefore, cancer needs to be investigated from systems biology point of view, we proposed the concept of “systems molecular imaging” for much better understanding systems biology of cancer.

This article revisits 18F-FDG uptake mechanisms, its oncology applications and the role of 18F-FDG PET for “systems molecular imaging”.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16647

Publication Alerts

Reviews:

Revisit 18F-fluorodeoxyglucose oncology positron emission tomography: “systems molecular imaging” of glucose metabolism

Abstract

Revisit ¹⁸F-fluorodeoxyglucose oncology positron emission tomography: “systems molecular imaging” of glucose metabolism